Compare

Hexarelin vs ITPP

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Hexarelin

1224 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 48% · Mixed 44% · Unfavorable overall 8%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
75
Energy
19
Mood
170
Focus
166
Sleep quality
76

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
171
Dizziness
99
Fatigue
135
Nausea
162
Water retention
75

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
7
50–100
15
100–200
23
200–400
12
400–600
7

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing28stacking21side effects14hexarelin7

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 28% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 32 days · Based on 269 repeat reporters

ITPP

763 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
38
Appetite control
150
Energy
51
Mood
106
Focus
91

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
134
GI discomfort
49
Dizziness
16
Fatigue
102
Nausea
90

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05 to ≥ 5 mg (open-ended top bucket)

0.05–0.1 mg
3
0.1–0.2 mg
6
0.2–0.4 mg
11
0.4–0.6 mg
22
0.6–1 mg
31
1–2 mg
25
2–3 mg
18
3–5 mg
11
5+ mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing47stacking25side effects33itpp21

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 29% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 168 repeat reporters

Sources (7)

Published sources linked on the Hexarelin and ITPP wiki pages.

  1. PubMed

    Hexarelin, a synthetic growth hormone-releasing peptide, vs GHRH in GH-deficient adults

    Ghigo E, Arvat E, Muccioli G, et al. Eur J Endocrinol. 1996

    Source
    Wiki study page →
  2. PubMed

    Hexarelin provides cardioprotective effects in rats

    Bisi G, Podio V, Valetto MR, et al. Growth Horm IGF Res. 2001

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    Hexarelin studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    The cardiovascular action of hexarelin

    Mao Y, Tokudome T, Kishimoto I. Journal of geriatric cardiology : JGC. 2014

    Source
    Wiki study page →
  5. PubMed

    Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

    Schneider MA, Linecker M, Fritsch R, et al. Nat Commun. 2021

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Effects of OXY111A (Myo-inositol trispyrophosphate) in Hepato-Pancreato-Biliary Neoplasms (NCT02528526)

    ClinicalTrials.gov. Clinical trial registry. 2015

    Source
    Wiki study page →